组蛋白去乙酰化酶抑制剂在肾脏疾病中的研究进展

Research Advancementsprogress onf the role of histone deacetylase inhibitors in kidney diseases

组蛋白去乙酰化酶(HDAC)可以诱导组蛋白和非组蛋白去乙酰化,在基因表达的表观遗传调节方面发挥重要作用。越来越多的证据表明HDAC参与各种肾脏疾病的发生、发展,强调抑制其活性可作为肾脏疾病的一种重要治疗策略。该文综述了组蛋白去乙酰化酶抑制剂在肾小管间质纤维化、糖尿病肾病、多囊肾病、急性肾损伤和狼疮性肾炎等肾脏疾病中的作用机制,以期为各种肾脏疾病的临床诊疗提供新靶点。

Histone deacetylase(HDAC)can induce deacetylation of both histone and non-histone proteins,and plays an important role in epigenetic regulation of gene expression.Increasing evidence has shown the involvement of HDAC in the development and progression of various renal diseases,highlighting the inhibition of HDAC as a promising therapeutic strategy to kidney diseases.This review focuses on the potential therapeutic effects and relevant mechanisms of HDAC inhibitors in kidney diseases including tubulointerstitial fibrosis,diabetic nephropathy,polycystic kidney disease,acute kidney injury and lupus nephritis,in order to provide new targets for clinical diagnosis and treatment of various renal diseases.